Kauppalehti

Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease

Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...

Idorsia Pharmaceuticals Ltd: Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease

Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...

Amtech signals continued AI-driven growth as panel-level packaging gains traction

The share of AI-related revenue in the Thermal Processing Solutions segment increased from 30% in Q4 2025 to 35% in Q1 2026, reflecting the ongoing strategic focus on AI infrastructure. Gross margin ...

ExGen Resources Inc: ExGen Resources Announces Results of Exploration on the Southmore Project in the Golden Triangle

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ExGen Resources Inc. (TSX.V: EXG; OTC: ...
Le Lézard

DPM Metals Extends Chelopech Mine Life to Ten Years; Provides Updated Mineral Reserve and Resource Estimate and Life of Mine Plan

DPM Metals Inc. (ARBN: 689370894) ("DPM" or "the Company") is pleased to announce an update to the Mineral Resource and Mineral Reserve ("MRMR") estimate and life of mine ("LOM") plan for its ...